Clinical trial
A Phase II Study of Avelumab Monotherapy in PD-L1 Positive or EBV Positive or MSI-H or POLE/POLD1 Mutated Advanced Solid Tumor (Part of K-BASKET Trial; Korea-Biomarker-driven Multi-arm Drug-screening, Knowledge and Evidence-generating Targeted Trial)
NCT03491345 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Avelumab Monotherapy in PD-L1 Positive or EBV Positive or MSI-H or POLE/POLD1 Mutated Advanced Solid Tumor (Part of K-BASKET Trial; Korea-Biomarker-driven Multi-arm Drug-screening, Knowledge and Evidence-generating Targeted Trial)
- Lead sponsor
- Yonsei University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 1, 2017
- Completion date
- December 31, 2022
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ebv positive mutation tumor, msi-h mutation tumor, pd-l1 positive mutation tumor, pole/pold1 mutation tumor